An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
Background: While the world is experiencing another wave of COVID-19 pandemic, global vaccination program is hampered by an evident shortage in the supply of licensed vaccines. In an effort to satisfy vaccine demands we developed a new single-dose vaccine based on recombinant adenovirus type 26 (rAd...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/54fc97d8b69745aa9da8b8b6bf909e3d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:54fc97d8b69745aa9da8b8b6bf909e3d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:54fc97d8b69745aa9da8b8b6bf909e3d2021-12-02T05:04:20ZAn open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults2666-776210.1016/j.lanepe.2021.100241https://doaj.org/article/54fc97d8b69745aa9da8b8b6bf909e3d2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666776221002271https://doaj.org/toc/2666-7762Background: While the world is experiencing another wave of COVID-19 pandemic, global vaccination program is hampered by an evident shortage in the supply of licensed vaccines. In an effort to satisfy vaccine demands we developed a new single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein – “Sputnik Light”. Methods: We conducted an open label, prospective, non-randomised phase 1/2 trial aimed to assess safety, tolerability, and immunogenicity of “Sputnik Light” vaccine in a single center in Russia. Primary outcome measures were antigen-specific humoral immunity (Anti-RBD-SARS-CoV-2 antibodies measured by ELISA on days 1, 10, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (measured by antigen-dependent CD4+ and CD8+ T-cell proliferation, number of antigen-specific interferon-γ-producing cells as well as interferon-γ concentration upon antigen restimulation) and change in neutralizing antibodies (measured in SARS-CoV-2 neutralization assay). Findings: Most of the solicited adverse reactions were mild (66·4% from all vaccinees), few were moderate (5·5%). No serious adverse events were detected. Assessment of Anti-RBD-SARS-CoV-2 antibodies revealed a group with pre-existing immunity to SARS-CoV-2. Upon this finding we separated all safety and immunogenicity data based on pre-existing immunity to SARS-CoV-2. There were notable differences in the vaccine effects on immunogenicity by the groups. Vaccination of seropositive (N=14) volunteers rapidly boosted RBD-specific IgGs from reciprocal geometric mean titer (GMT) 594·4 at a baseline up to 26899 comparing to 29·09 in seronegative group (N=96) by day 10. By day 42 seroconversion rate reached 100% (93/93) in seronegative group with GMT 1648. At the same time, in the seropositive group, seroconversion rate by day 42 was 92·9% (13/14) with GMT 19986. Analysis of neutralizing antibodies to SARS-CoV-2 showed 81·7% (76/93) and 92·9% (13/14) seroconversion rates by day 42 with median reciprocal GMT 15·18 and 579·7 in the seronegative and seropositive groups, respectively. Antigen-specific T cell proliferation, formation of IFNy-producing cells, and IFNy secretion were observed in 96·7% (26/27), 96% (24/25), and 96% (24/25) of the seronegative group respectively and in 100% (3/3), 100% (5/5), and 100% (5/5) of the seropositive vaccinees, respectively. Interpretation: The single-dose rAd26 vector-based COVID-19 vaccine “Sputnik Light” has a good safety profile and induces a strong humoral and cellular immune responses both in seronegative and seropositive participants. Funding: Russian Direct Investment Fund.Amir I. TukhvatulinInna V. DolzhikovaDmitry V. ShcheblyakovOlga V. ZubkovaAlina S. DzharullaevaAnna V. KovyrshinaNadezhda L. LubenetsDaria M. GrousovaAlina S. ErokhovaAndrei G. BotikovFatima M. IzhaevaOlga PopovaTatiana A. OzharovskaiaIlias B. EsmagambetovIrina A. FavorskayaDenis I. ZrelkinDaria V. VoroninaDmitry N. ShcherbininAlexander S. SemikhinYana V. SimakovaElizaveta A. TokarskayaMaksim M. ShmarovNatalia A. NikitenkoVladimir A. GushchinElena A. SmolyarchukTatiana G. ZubkovaKonstantin A. ZakharovVasiliy B. VasilyukSergei V. BorisevichBoris S. NaroditskyDenis Y. LogunovAlexander L. GintsburgElsevierarticlePublic aspects of medicineRA1-1270ENThe Lancet Regional Health. Europe, Vol 11, Iss , Pp 100241- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Public aspects of medicine RA1-1270 |
| spellingShingle |
Public aspects of medicine RA1-1270 Amir I. Tukhvatulin Inna V. Dolzhikova Dmitry V. Shcheblyakov Olga V. Zubkova Alina S. Dzharullaeva Anna V. Kovyrshina Nadezhda L. Lubenets Daria M. Grousova Alina S. Erokhova Andrei G. Botikov Fatima M. Izhaeva Olga Popova Tatiana A. Ozharovskaia Ilias B. Esmagambetov Irina A. Favorskaya Denis I. Zrelkin Daria V. Voronina Dmitry N. Shcherbinin Alexander S. Semikhin Yana V. Simakova Elizaveta A. Tokarskaya Maksim M. Shmarov Natalia A. Nikitenko Vladimir A. Gushchin Elena A. Smolyarchuk Tatiana G. Zubkova Konstantin A. Zakharov Vasiliy B. Vasilyuk Sergei V. Borisevich Boris S. Naroditsky Denis Y. Logunov Alexander L. Gintsburg An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| description |
Background: While the world is experiencing another wave of COVID-19 pandemic, global vaccination program is hampered by an evident shortage in the supply of licensed vaccines. In an effort to satisfy vaccine demands we developed a new single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein – “Sputnik Light”. Methods: We conducted an open label, prospective, non-randomised phase 1/2 trial aimed to assess safety, tolerability, and immunogenicity of “Sputnik Light” vaccine in a single center in Russia. Primary outcome measures were antigen-specific humoral immunity (Anti-RBD-SARS-CoV-2 antibodies measured by ELISA on days 1, 10, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (measured by antigen-dependent CD4+ and CD8+ T-cell proliferation, number of antigen-specific interferon-γ-producing cells as well as interferon-γ concentration upon antigen restimulation) and change in neutralizing antibodies (measured in SARS-CoV-2 neutralization assay). Findings: Most of the solicited adverse reactions were mild (66·4% from all vaccinees), few were moderate (5·5%). No serious adverse events were detected. Assessment of Anti-RBD-SARS-CoV-2 antibodies revealed a group with pre-existing immunity to SARS-CoV-2. Upon this finding we separated all safety and immunogenicity data based on pre-existing immunity to SARS-CoV-2. There were notable differences in the vaccine effects on immunogenicity by the groups. Vaccination of seropositive (N=14) volunteers rapidly boosted RBD-specific IgGs from reciprocal geometric mean titer (GMT) 594·4 at a baseline up to 26899 comparing to 29·09 in seronegative group (N=96) by day 10. By day 42 seroconversion rate reached 100% (93/93) in seronegative group with GMT 1648. At the same time, in the seropositive group, seroconversion rate by day 42 was 92·9% (13/14) with GMT 19986. Analysis of neutralizing antibodies to SARS-CoV-2 showed 81·7% (76/93) and 92·9% (13/14) seroconversion rates by day 42 with median reciprocal GMT 15·18 and 579·7 in the seronegative and seropositive groups, respectively. Antigen-specific T cell proliferation, formation of IFNy-producing cells, and IFNy secretion were observed in 96·7% (26/27), 96% (24/25), and 96% (24/25) of the seronegative group respectively and in 100% (3/3), 100% (5/5), and 100% (5/5) of the seropositive vaccinees, respectively. Interpretation: The single-dose rAd26 vector-based COVID-19 vaccine “Sputnik Light” has a good safety profile and induces a strong humoral and cellular immune responses both in seronegative and seropositive participants. Funding: Russian Direct Investment Fund. |
| format |
article |
| author |
Amir I. Tukhvatulin Inna V. Dolzhikova Dmitry V. Shcheblyakov Olga V. Zubkova Alina S. Dzharullaeva Anna V. Kovyrshina Nadezhda L. Lubenets Daria M. Grousova Alina S. Erokhova Andrei G. Botikov Fatima M. Izhaeva Olga Popova Tatiana A. Ozharovskaia Ilias B. Esmagambetov Irina A. Favorskaya Denis I. Zrelkin Daria V. Voronina Dmitry N. Shcherbinin Alexander S. Semikhin Yana V. Simakova Elizaveta A. Tokarskaya Maksim M. Shmarov Natalia A. Nikitenko Vladimir A. Gushchin Elena A. Smolyarchuk Tatiana G. Zubkova Konstantin A. Zakharov Vasiliy B. Vasilyuk Sergei V. Borisevich Boris S. Naroditsky Denis Y. Logunov Alexander L. Gintsburg |
| author_facet |
Amir I. Tukhvatulin Inna V. Dolzhikova Dmitry V. Shcheblyakov Olga V. Zubkova Alina S. Dzharullaeva Anna V. Kovyrshina Nadezhda L. Lubenets Daria M. Grousova Alina S. Erokhova Andrei G. Botikov Fatima M. Izhaeva Olga Popova Tatiana A. Ozharovskaia Ilias B. Esmagambetov Irina A. Favorskaya Denis I. Zrelkin Daria V. Voronina Dmitry N. Shcherbinin Alexander S. Semikhin Yana V. Simakova Elizaveta A. Tokarskaya Maksim M. Shmarov Natalia A. Nikitenko Vladimir A. Gushchin Elena A. Smolyarchuk Tatiana G. Zubkova Konstantin A. Zakharov Vasiliy B. Vasilyuk Sergei V. Borisevich Boris S. Naroditsky Denis Y. Logunov Alexander L. Gintsburg |
| author_sort |
Amir I. Tukhvatulin |
| title |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| title_short |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| title_full |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| title_fullStr |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| title_full_unstemmed |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults |
| title_sort |
open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “sputnik light” for prevention of coronavirus infection in healthy adults |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/54fc97d8b69745aa9da8b8b6bf909e3d |
| work_keys_str_mv |
AT amiritukhvatulin anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT innavdolzhikova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dmitryvshcheblyakov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT olgavzubkova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alinasdzharullaeva anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT annavkovyrshina anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT nadezhdallubenets anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dariamgrousova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alinaserokhova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT andreigbotikov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT fatimamizhaeva anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT olgapopova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT tatianaaozharovskaia anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT iliasbesmagambetov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT irinaafavorskaya anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT denisizrelkin anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dariavvoronina anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dmitrynshcherbinin anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alexanderssemikhin anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT yanavsimakova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT elizavetaatokarskaya anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT maksimmshmarov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT nataliaanikitenko anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT vladimiragushchin anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT elenaasmolyarchuk anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT tatianagzubkova anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT konstantinazakharov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT vasiliybvasilyuk anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT sergeivborisevich anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT borissnaroditsky anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT denisylogunov anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alexanderlgintsburg anopennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT amiritukhvatulin opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT innavdolzhikova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dmitryvshcheblyakov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT olgavzubkova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alinasdzharullaeva opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT annavkovyrshina opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT nadezhdallubenets opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dariamgrousova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alinaserokhova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT andreigbotikov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT fatimamizhaeva opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT olgapopova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT tatianaaozharovskaia opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT iliasbesmagambetov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT irinaafavorskaya opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT denisizrelkin opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dariavvoronina opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT dmitrynshcherbinin opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alexanderssemikhin opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT yanavsimakova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT elizavetaatokarskaya opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT maksimmshmarov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT nataliaanikitenko opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT vladimiragushchin opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT elenaasmolyarchuk opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT tatianagzubkova opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT konstantinazakharov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT vasiliybvasilyuk opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT sergeivborisevich opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT borissnaroditsky opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT denisylogunov opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults AT alexanderlgintsburg opennonrandomisedphase12trialonthesafetytolerabilityandimmunogenicityofsingledosevaccinesputniklightforpreventionofcoronavirusinfectioninhealthyadults |
| _version_ |
1718400649966649344 |